

**RECEIVED  
CENTRAL FAX CENTER****JUN 06 2006****PATENT****IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

<b>Inventor(s):</b> Clifton A. Alferness	<b>Examiner:</b> GETZOW, Scott M.
<b>Appln. No.:</b> 10/668,918	<b>Group Art Unit:</b> 3762
<b>Filing Date:</b> September 23, 2003	<b>Confirmation No.:</b> 2651
<b>Title:</b> CARDIAC REINFORCEMENT DEVICE	<b>Customer No.:</b> 25764
	<b>Docket No.</b> 59013-331609

**Mail Stop Amendment**  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

I CERTIFY THAT THIS CORRESPONDENCE IS BEING  
FACSIMILE TRANSMITTED TO THE U.S. PATENT AND  
TRADEMARK OFFICE (FAX NO. (571) 273-8300), ON  
JUNE 6, 2006

  
ELAINE RAITEN

**RESPONSE**

This Response is in reply to the outstanding Office Action mailed January 6, 2006,  
and includes the following section:

1. Introductory Comments, beginning on page 2 of this paper;
2. Listing of Claims beginning on page 3; and
3. Remarks beginning on page 5.

Also enclosed are the following documents:

1. Two-Month Extension of Time,
2. Credit Card Payment Form for extension of time and terminal disclaimer fees,
3. Terminal Disclaimer over pending applications, and
4. Terminal Disclaimer over patents.

Should any additional fee be required for entry of this paper, the Commissioner is  
authorized to charge the Faegre & Benson Deposit Account No. 06-0029 and in such event,  
is requested to notify us of the same.

A.N.: 10/668,918  
Reply to Office Action of January 6, 2006  
Docket No.: 59013-331609  
Page 2

### **INTRODUCTORY COMMENTS**

This communication is fully responsive to the Office Action set forth above. Claims 28-35 are pending in the current application. In the above-identified Office Action, the Examiner rejected claim 28-35.

By this Response, the Applicant hereby submits terminal disclaimers to obviate rejections on the ground of nonstatutory obviousness-type double patenting. The Applicant traverses the Examiner's rejection of claims 28-35 under 35 U.S.C. § 102(e). Reconsideration and allowance of claims 28-35 in view of these terminal disclaimers and the accompanying Remarks is respectfully requested.